Deciphera Pharmaceuticals今日宣布，已与ONO Pharmaceutical达成确定性的合并协议。根据该协议，ONO将斥资约24亿美元收购Deciphera。通过此次合并，ONO和Deciphera将加速实现它们的共同愿景，向全球患者提供创新药物。 Deciphera拥有激酶药物发现和开发的专长，以及在美国和 ...

Deciphera Pharmaceuticals(DCPH.US)周一宣布，日本小野药品工业(OPHLY.US)已同意以24亿美元的总股本价值收购这家癌症药物开发商。受此消息提振，截至发稿，Deciphera 盘前大涨71%。 据悉，小野药品工业将通过要约收购方式，以每股25.60美元价格现金收购Deciphera普通股的 ...

Deciphera是一家药品研发公司，其药品主要是用于癌症治疗，专注于发现，开发和提供重要的新药给病人治疗癌症。该公司正在利用其专有的开关控制激酶抑制剂平台和激酶生物学的深厚专业知识来执行他们的战略，以开发广泛的创新药物组合。近日，小野制药 ...

Deciphera Pharmaceuticals, Inc. DCPH announced that it has dosed the first patient in a phase I study which is evaluating its investigational ULK kinase inhibitor, DCC-3116, for the treatment of ...

OSAKA, Japan & WALTHAM, Mass., November 17, 2025--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; "Ono"), today announced the opening of a ...

Deciphera Pharmaceuticals, Inc. DCPH announced an outlook and planned corporate milestones for 2023. The company outlined certain commercial, clinical and preclinical activities for the year. Along ...

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that it will report its first quarter 2021 financial results on Tuesday, May 4, 2021. In connection with ...

On Monday, Japanese pharma company ONO Pharmaceutical agreed to acquire Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) for $25.60 per share in cash, for a total equity value of $2.4 billion. Deciphera ...

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve ...

Deciphera Pharmaceuticals (NASDAQ:DCPH) announced Monday that its experimental therapy, vimseltinib, reached the primary endpoint and all key secondary endpoints in a Phase 3 trial for patients with ...

Our estimates show that Qinlock 2L KIT exon 11+17/18 mutation indication sales guidance is unlikely to be achieved due to fractional incidence. Deciphera Pharmaceuticals is expecting a Phase III ...